Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.
Rebecka Ventin-HolmbergAnja EberlSchahzad SaqibKatri KorpelaSeppo VirtanenTaina SipponenAnne SalonenPäivi SaavalainenEija NissiläPublished in: Journal of Crohn's & colitis (2021)
Faecal bacterial and fungal microbiota composition could provide a predictive tool to estimate IFX response in IBD patients.